4-(4-TERT-BUTYLPHENOXY)-N-(6-(4,5-DIMETHOXY-2-METHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)HEXYL)-N-METHYLBENZAMIDE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	AHZRATHNZGOJJY-UHFFFAOYSA-N
Smiles	COC1=C(OC)C(=O)C(=C(C)C1=O)CCCCCCN(C)C(=O)c2ccc(Oc3ccc(cc3)C(C)(C)C)cc2
InChI	InChI=1S/C33H41NO6/c1-22-27(29(36)31(39-7)30(38-6)28(22)35)12-10-8-9-11-21-34(5)32(37)23-13-17-25(18-14-23)40-26-19-15-24(16-20-26)33(2,3)4/h13-20H,8-12,21H2,1-7H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C33H41NO6
Molecular Weight	547.68
AlogP	6.57
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	13.0
Polar Surface Area	82.14
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	40.0

Assay Description	Organism	Bioactivity
Inhibition of Bos taurus (bovine) mitochondrial complex 3 electron transfer activity measured per mg of protein	Bos taurus	1.1 micromol/min
Inhibition of Bos taurus (bovine) mitochondrial complex 3 electron transfer activity	Bos taurus	5500.0 nM
Inhibition of Bos taurus (bovine) mitochondrial complex 2 electron transfer activity measured per mg of protein	Bos taurus	0.011 micromol/min
Inhibition of Bos taurus (bovine) mitochondrial complex 2 electron transfer activity	Bos taurus	2000.0 nM
Inhibition of Bos taurus (bovine) mitochondrial complex 1 assessed as reduction in enzyme activity by NADH-DU oxidoreductase assay	Bos taurus	610.0 nM
Inhibition of Bos taurus (bovine) mitochondrial complex 1 assessed as reduction in enzyme activity by NADH-HU oxidoreductase assay	Bos taurus	1100.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2272027
PubChem	76334248

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).